New antifungal drug fosmanogepix tested in healthy volunteers
NCT ID NCT06961708
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial studied the safety and how the body handles the experimental antifungal drug fosmanogepix in 54 healthy Chinese adults. Participants received single or multiple doses of the drug either by mouth or through an IV, or a placebo. The study measured drug levels in the blood and monitored for side effects to guide future dosing in patients with fungal infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
fosmanogepix
What this could lead to
If successful, this study will provide key dosing and safety data for fosmanogepix, potentially supporting its use against serious fungal infections.
What could go wrong
This is an early Phase 1 trial in healthy volunteers, not patients. It only measures safety and drug levels, not whether the drug works against infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Xuhui Central Hospital, Longchuan North Road
Shanghai, 200237, China